Applied Therapeutics, Inc.
APLT
$0.3987
$0.00040.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 456.00K | -211.00K | -333.00K | -477.00K | 9.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 456.00K | -211.00K | -333.00K | -477.00K | 9.99M |
| Cost of Revenue | 48.74M | 52.35M | 48.31M | 50.19M | 53.91M |
| Gross Profit | -48.29M | -52.56M | -48.64M | -50.67M | -43.91M |
| SG&A Expenses | 56.01M | 39.72M | 29.39M | 24.11M | 20.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.75M | 92.07M | 77.70M | 74.30M | 74.53M |
| Operating Income | -104.30M | -92.28M | -78.04M | -74.77M | -64.54M |
| Income Before Tax | -105.62M | -187.31M | -161.09M | -193.56M | -119.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.62 | -187.31 | -161.09 | -193.56 | -119.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.62M | -187.31M | -161.09M | -193.56M | -119.76M |
| EBIT | -104.30M | -92.28M | -78.04M | -74.77M | -64.54M |
| EBITDA | -104.30M | -92.28M | -78.04M | -74.77M | -64.54M |
| EPS Basic | -0.82 | -1.47 | -1.46 | -1.85 | -1.36 |
| Normalized Basic EPS | -0.51 | -0.92 | -0.91 | -1.16 | -0.85 |
| EPS Diluted | -0.97 | -1.62 | -1.61 | -1.85 | -1.36 |
| Normalized Diluted EPS | -0.51 | -0.92 | -0.91 | -1.16 | -0.85 |
| Average Basic Shares Outstanding | 558.06M | 524.13M | 470.45M | 405.56M | 336.60M |
| Average Diluted Shares Outstanding | 566.52M | 532.59M | 478.91M | 405.56M | 336.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |